Firacative Carolina, Vélez Norida, Kissmann Ann-Kathrin, Alpízar-Pedraza Daniel, Walter Jan-Christoph, Ständker Ludger, Rosenau Frank
Studies in Translational Microbiology and Emerging Diseases (MICROS) Research Group, School of Medicine and Health Sciences, Universidad de Rosario, Bogota 111221, Colombia.
Institute of Pharmaceutical Biotechnology, Ulm University, 89081 Ulm, Germany.
Pathogens. 2025 May 22;14(6):511. doi: 10.3390/pathogens14060511.
The World Health Organization (WHO) prioritized 19 fungal species based on the significant impact of these pathogens on human health, including the emergence of antifungal resistance, which highlights the necessity of finding new antifungal therapies. Among these novel therapeutic approaches, the antimicrobial pore-forming peptide C14R has shown to be promising against and . In this study, the antifungal in vitro efficacy of C14R was assessed against six additional species from the WHO priority list, , , , , and , as well as against This study shows that C14R has good antifungal activity against several clinical isolates of the studied species, with MIC values between 0.8476 and 10.88 µg/mL. Most notably, some of the studied isolates are resistant to commonly used antifungal drugs but are susceptible to the peptide. C14R showed, moreover, its capacity to disrupt capsules, beyond its already proven capacity to disrupt plasma membranes, and its antifungal activity was not affected depending on the serotype or species assessed. The inclusion of basidiomycete and ascomycete yeasts allowed us to display the broad-spectrum potential of C14R, highlighting it as a promising candidate as an antifungal agent.
世界卫生组织（WHO）根据19种真菌病原体对人类健康的重大影响对其进行了优先排序，其中包括抗真菌耐药性的出现，这凸显了寻找新型抗真菌疗法的必要性。在这些新型治疗方法中，抗菌成孔肽C14R已显示出对[具体两种真菌]有前景。在本研究中，评估了C14R对世界卫生组织优先清单中的另外六种真菌的体外抗真菌效果，即[六种真菌名称]，以及对[另一种真菌]的效果。本研究表明，C14R对所研究真菌的几种临床分离株具有良好的抗真菌活性，MIC值在0.8476至10.88 µg/mL之间。最值得注意的是，一些所研究的分离株对常用抗真菌药物耐药，但对该肽敏感。此外，C14R除了已被证实的破坏质膜的能力外，还显示出破坏[具体结构]荚膜的能力，并且其抗真菌活性不受所评估的血清型或物种的影响。纳入担子菌酵母和子囊菌酵母使我们能够展示C14R的广谱潜力，突出其作为一种有前景的抗真菌剂候选物的地位。
